Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AIMMUNE THERAPEUTICS, INC.

(AIMT)
SummaryChartsNewsRatingsCompany 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Aimmune Therapeutics : shareholders accept $2 billion Nestle tender offer

10/13/2020 | 01:39am EDT
Capsules of Palforzia are shown containing pharmaceutical grade peanut powder, for use in oral immunotherapy among patients with peanut allergies, manufactured by Aimmune Therapeutics

ZURICH (Reuters) - Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

Including shares it already held, Nestle controlled around 84% of the outstanding shares as of the $34.50 per share offer's expiration date. "The minimum tender condition to the consummation of the offer set forth in the offer to purchase has been satisfied," Nestle said.

(Reporting by Michael Shields, editing by Kirsti Knolle)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
NESTLÉ S.A. 0.61% 115.46 Delayed Quote.10.07%
All news about AIMMUNE THERAPEUTICS, INC.
02/18PRESS RELEASE : Nestle: Nestlé reports full-year -2-
DJ
01/22AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
01/05AIMMUNE THERAPEUTICS  : European Commission approves first treatment for peanut ..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission approves Aimmune's PALFORZIA as firs..
AQ
2020AIMMUNE THERAPEUTICS  : European Commission Approves Aimmune's PALFORZIA® as Fir..
BU
2020Nestle shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
2020AIMMUNE THERAPEUTICS, INC.  : Termination of a Material Definitive Agreement, Co..
AQ
2020AIMMUNE THERAPEUTICS  : Receives Positive CHMP Opinion on PALFORZIA for the Trea..
AQ
2020MONTEVERDE & ASSOCIATES PC  : Files Class Action Lawsuit On Behalf Of Shareholde..
PR
2020AIMMUNE THERAPEUTICS  : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
More news
Chart AIMMUNE THERAPEUTICS, INC.
Duration : Period :
Aimmune Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers and Directors
NameTitle
Mark D. McDade Chairman
Daniel C. Adelman Chief Medical Officer
Narinder Singh Executive Vice President-Technical Operations
Patrick G. Enright Independent Non-Employee Director
Stacey Denenberg Seltzer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AIMMUNE THERAPEUTICS, INC.0.00%2 268
GILEAD SCIENCES, INC.15.57%84 444
WUXI APPTEC CO., LTD.21.14%62 089
REGENERON PHARMACEUTICALS8.38%54 220
BIONTECH SE150.06%49 234
VERTEX PHARMACEUTICALS-20.67%48 535